News >

Update Details Brentuximab Vedotin Survival Benefit in CD30+ PTCL

Gina Columbus @ginacolumbusonc
Published: Wednesday, Dec 05, 2018

Steven Horwitz, MD

Steven Horwitz, MD

The addition of brentuximab vedotin (Adcetris) to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma (PTCL), according to phase III results of the ECHELON-2 trial presented at the 2018 ASH Annual Meeting and published online at Lancet Oncology.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication